Plus therapeutics presents positive respect-lm phase 1 interim data for leptomeningeal metastases at the 2024 sno annual conference

Single intrathecal dose of rhenium ( 186 re) obisbemeda shows a favorable response rate and median overall survival in leptomeningeal metastases (lm) patients achieves up to 8x absorbed radiation dose to the cns subarachnoid space vs. standard of care external beam radiation receives fda agreement to initiate the respect-lm phase 1 multiple administration dose escalation trial of rhenium ( 186 re) obisbemeda for lm austin, texas, nov. 25, 2024 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (“plus” or the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, presented data updating the progress of its respect-lm phase 1 clinical trial of rhenium (186re) obisbemeda (rhenium nanoliposome, 186rnl) in leptomeningeal disease (lm).
PSTV Ratings Summary
PSTV Quant Ranking